We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

239 hedge funds and large institutions have $2.88B invested in Nektar Therapeutics in 2021 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 74 increasing their positions, 79 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 21

2% more funds holding

Funds holding: 235 → 239 (+4)

0.07% less ownership

Funds ownership: 6.22% → 6.15% (-0.07%)

5% less call options, than puts

Call options by funds: $11.1M | Put options by funds: $11.8M

6% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 79

15% less capital invested

Capital invested by funds: $3.39B → $2.88B (-$509M)

Holders
239
Holders Change
+4
Holders Change %
+1.7%
% of All Funds
4.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
25
Increased
74
Reduced
79
Closed
21
Calls
$11.1M
Puts
$11.8M
Net Calls
-$642K
Net Calls Change
-$1.34M

Top Buyers

1
CCM
Camber Capital Management
Massachusetts
+$27.7M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$12.1M
3
Millennium Management
Millennium Management
New York
+$8.64M
4
State Street
State Street
Massachusetts
+$6.81M
5
Two Sigma Investments
Two Sigma Investments
New York
+$5.57M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$36.6M
2
Ameriprise
Ameriprise
Minnesota
-$30.9M
3
First Trust Advisors
First Trust Advisors
Illinois
-$16.5M
4
BlackRock
BlackRock
New York
-$7.95M
5
PI
Putnam Investments
Massachusetts
-$7.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
201
Financial Perspectives
Minnesota
$13.4K -$273K -988 -95%
ACA
202
Atlas Capital Advisors
Wyoming
$10.3K – – –
ST
203
Sageworth Trust
Pennsylvania
$10K +$11.3K +41 New
SWA
204
Sutton Wealth Advisors
Florida
$9.63K – – –
GWM
205
Geneos Wealth Management
Colorado
$9K – – –
SIAP
206
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$9K – – –
GAM
207
Gemmer Asset Management
California
$9K +$3.6K +13 +65%
MFA
208
McClarren Financial Advisors
Pennsylvania
$8K +$6.09K +22 +220%
First Manhattan
209
First Manhattan
New York
$8K +$9.13K +33 New
NFG
210
Next Financial Group
Texas
$7K -$277 -1 -4%
MAM
211
Meeder Asset Management
Ohio
$7K +$6.37K +23 +575%
Daiwa Securities Group
212
Daiwa Securities Group
Japan
$6K – – –
Rockefeller Capital Management
213
Rockefeller Capital Management
New York
$6K – – –
AIG
214
American International Group
New York
$5.56K -$115K -416 -2%
AWM
215
AllSquare Wealth Management
New York
$5K – – –
HI
216
Harbour Investments
Wisconsin
$5K – – –
LWANC
217
Laurel Wealth Advisors (North Carolina)
North Carolina
$5K – – –
APA
218
American Portfolios Advisors
New York
$4.8K -$830 -3 -14%
FDCDDQ
219
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.55K – – –
ST
220
Smithfield Trust
Pennsylvania
$4K – – –
QCG
221
Quadrant Capital Group
Ohio
$3K – – –
TWA
222
TCI Wealth Advisors
Arizona
$3K +$3.04K +11 +550%
Carson Wealth (CWM LLC)
223
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
NSIM
224
North Star Investment Management
Illinois
$2K – – –
SWM
225
Sugarloaf Wealth Management
Georgia
$2K – – –
7 8
9
10 11

NKTR Hedge Fund Activity: Q2 2021 in Review

239 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2021, worth a combined $2.88B — down 15% from $3.39B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NKTR positions and 21 closed out — a net gain of 4 holders — while 74 added to existing stakes and 79 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $27.7M. The largest seller was Fidelity Investments, cutting an estimated $36.6M.

  • 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2021, up from 235 in Q1 2021.
  • Funds reported $2.88B of Nektar Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
  • 25 funds opened new Nektar Therapeutics positions in Q2 2021 and 21 closed out, a net change of +4 holders.
  • The largest Nektar Therapeutics buyer in Q2 2021 was Camber Capital Management, an estimated $27.7M added.
  • The largest Nektar Therapeutics seller in Q2 2021 was Fidelity Investments, an estimated $36.6M sold.

Based on aggregated 13F filings for Q2 2021.